parapsoriasis: one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying etiology. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
165 |
4. Check minimum number of eventsNone |
165 |
5. Include endpointsNone |
165 |
6. Filter based on genotype QC (FinnGen only) |
144 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L41
- Name in latin
- Pityriasis lichenoides chronica
Similar endpoints
↥List of similar endpoints to
Pityriasis lichenoides chronica
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1094 | 573 | 516 |
| Only index persons | 1012 | 541 | 471 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 47.37 | 51.09 | 43.22 |
| Only index persons | 46.68 | 50.15 | 42.71 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 144 | 76 | 68 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 56.06 | 53.99 | 58.38 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 149
- Matched controls
- 1490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L41.1
ICD-10 Finland
Pityriasis lichenoides chronica
+∞
201.6
144
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
17.9
67.9
71
72
L30.9
ICD-10 Finland
Dermatitis, unspecified
8.5
39.2
80
178
D07AC01
ATC
betamethasone; topical
7.2
31.9
98
314
E0000UV, ,
ATC
7.2
28.8
110
419
D07AD01
ATC
clobetasol; topical
6.6
25.3
53
115
D07AB02
ATC
hydrocortisone butyrate; topical
5.4
23.7
84
288
D07AB08
ATC
desonide; topical
6.4
22.4
46
97
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
242.5
21.1
21
*
D07AC13
ATC
mometasone; topical
4.7
19.4
72
248
D02AE01
ATC
carbamide; topical
8.0
16.2
24
35
L40.0
ICD-10 Finland
Psoriasis vulgaris
63.4
15.1
17
*
E000002, ,
ATC
4.9
13.2
34
85
E000001, ,
ATC
3.9
12.9
52
182
D07BA04
ATC
hydrocortisone and antiseptics; topical
4.9
12.9
33
82
L41.4
ICD-10 Finland
Large plaque parapsoriasis
+∞
12.7
12
*
D07XC01
ATC
betamethasone; topical
4.8
11.6
30
75
L43.8
ICD-10 Finland
Other lichen planus
118.0
10.6
11
*
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
5.9
9.9
19
36
XQ848
NOMESCO Finland
Dermatological photography
11.8
9.6
17
16
L41.0
ICD-10 Finland
Pityriasis lichenoides et varioliformis acuta
+∞
9.5
9
*
D07AA02
ATC
hydrocortisone; topical
3.4
8.2
35
124
E000007, ,
ATC
4.7
7.0
17
40
D05AX52
ATC
calcipotriol, combinations; topical
10.0
6.9
13
14
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
3.1
6.9
33
125
D02AX
ATC
Other emollients and protectives
8.5
6.8
14
18
D05AX02
ATC
calcipotriol; topical
23.8
6.8
9
*
D09AB01
ATC
zinc bandage without supplements; topical
13.1
6.7
11
9
TQW80
NOMESCO Finland
Local dermatologic skincare
10.8
6.7
12
12
H02AB06
ATC
prednisolone; systemic
2.3
6.0
83
522
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
154
2.56
5.01
3.6
4.8
231.76
237.90
u/l
0.18
34
146
44
254
2.04
3.59
1.4
1.3
30.15
29.16
iu/ml
0.02
12
86
40
232
1.99
3.19
1.3
1.3
2.34
11.81
u/ml
1.24
12
84
7
12
6.06
3.05
1.3
1.1
—
—
—
0
0
62
428
1.77
2.83
3.9
3.9
3.80
7.64
mg/mmol
1.12
35
266
39
233
1.91
2.83
4.9
3.6
171.00
244.67
ng/l
0.16
25
182
96
754
1.77
2.76
11.8
10.4
4.00
4.15
e9/l
0.33
88
663
76
573
1.67
2.43
5.0
5.4
35.32
35.58
g/l
0.16
68
551
12
46
2.75
2.42
1.4
2.0
0.26
0.23
g/l
0.55
12
46
12
46
2.75
2.42
1.4
2.0
1.20
1.17
g/l
0.26
12
46
115
972
1.80
2.36
6.0
4.3
11.28
11.61
mm/h
0.11
108
899
52
361
1.68
2.24
2.8
3.2
335.21
339.99
umol/l
0.13
47
315
61
454
1.58
1.95
3.8
3.5
2.34
2.35
mmol/l
0.64
56
417
46
329
1.58
1.71
1.5
1.4
1.74
2.19
u/ml
0.15
18
88
114
1000
1.60
1.61
8.2
8.3
77.69
80.24
u/l
0.28
109
940
6
20
3.08
1.60
1.3
2.1
—
—
—
0
0
111
969
1.57
1.59
5.5
4.5
15.16
14.83
pmol/l
0.66
103
879
66
520
1.48
1.55
2.3
2.0
1.40
1.33
mmol/l
0.20
58
432
11
51
2.25
1.55
1.1
1.4
417.62
257.08
miu/ml
—
6
26
5
15
3.41
1.53
2.6
3.1
—
—
—
0
0
5
15
3.41
1.53
1.0
1.1
—
—
—
0
0
6
21
2.93
1.52
1.0
1.1
—
—
—
0
0
9
40
2.33
1.43
1.8
1.5
—
—
—
0
0
10
47
2.21
1.37
1.4
1.2
—
2.05
—
0
8
5
17
3.01
1.37
1.0
1.2
—
—
—
0
0
5
19
2.69
1.22
1.0
1.2
—
—
—
0
0
5
19
2.69
1.22
1.0
1.2
—
—
—
0
0
5
19
2.69
1.22
1.0
1.2
—
—
—
0
0
72
597
1.40
1.21
2.6
2.6
87.49
77.08
nmol/l
1.67
66
530
7
31
2.32
1.12
1.6
1.3
1803.57
5766.11
e6/l
—
7
19
7
31
2.32
1.12
1.6
1.2
—
—
—
0
0
39
294
1.44
1.10
5.2
4.3
1.02
1.02
kg/l
0.35
28
198
44
340
1.42
1.09
2.4
2.5
2.32
2.99
mg/l
1.35
39
296
7
34
2.11
1.04
1.1
1.5
—
—
—
0
0
5
22
2.32
1.04
1.0
1.1
—
—
—
0
0
40
309
1.40
0.99
1.9
2.1
1.14
1.60
mg/l
0.46
31
248
5
23
2.21
0.99
1.0
1.6
0.13
0.32
nmol/l
—
5
17
115
1050
1.42
0.99
27.2
21.2
13.59
13.68
%
0.32
115
1041
41
324
1.37
0.88
5.0
4.8
18.27
22.14
%
0.96
14
168
8
45
1.82
0.86
1.1
1.2
—
—
—
0
0
133
1257
1.54
0.85
18.5
17.2
20.98
23.52
mg/l
0.45
112
1023
77
671
1.31
0.85
6.5
8.3
1.22
1.21
mmol/l
0.52
69
576
0
24
0.00
0.80
0.0
1.0
—
—
—
0
0
28
211
1.40
0.80
2.0
2.4
28.78
29.17
s
0.19
28
206
9
53
1.74
0.77
2.9
3.1
0.00
1.18
g/l
—
9
48
34
267
1.35
0.76
1.8
1.8
617.44
453.05
pmol/l
0.94
29
226
61
525
1.27
0.71
5.1
4.2
0.00
0.02
estimate
0.50
16
125
111
1182
0.76
0.69
4.3
4.4
1.29
1.26
mmol/l
0.15
98
1085
47
393
1.29
0.68
4.6
3.6
0.00
0.00
estimate
-0.00
15
122
5
28
1.81
0.67
1.0
1.6
—
—
—
0
0
124
1170
1.36
0.66
6.9
5.4
1.90
1.95
mu/l
0.20
115
1069
15
104
1.49
0.65
1.1
1.4
—
—
—
0
0
138
1327
1.54
0.64
24.3
21.8
73.68
77.65
umol/l
1.58
138
1312
0
20
0.00
0.61
0.0
1.6
—
—
—
0
0
10
64
1.60
0.60
1.4
1.7
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
30
241
1.31
0.58
1.9
1.7
—
—
—
0
0
6
35
1.74
0.58
1.0
1.7
—
—
—
0
0
19
142
1.39
0.58
2.5
2.2
302.37
394.77
nmol/l
1.29
19
133
28
227
1.29
0.51
1.5
1.7
1338.69
1219.72
nmol/l
0.33
18
173
25
200
1.30
0.51
3.1
6.0
1.04
1.05
mmol/l
0.06
19
184
11
76
1.48
0.49
1.4
1.9
—
—
—
0
0
64
573
1.20
0.49
2.2
2.1
94.33
95.57
pmol/l
0.07
35
286
7
48
1.48
0.47
1.4
1.4
—
—
—
0
0
24
194
1.28
0.45
3.6
8.1
102.79
103.80
mmol/l
0.40
24
194
5
32
1.58
0.42
1.2
1.7
—
—
—
0
0
5
32
1.58
0.42
1.4
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
5.1
—
110.17
—
0
16
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
5
34
1.49
0.40
2.2
1.4
—
0.09
—
0
8
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
27
226
1.24
0.39
1.5
1.9
—
—
—
0
0
0
19
0.00
0.39
0.0
3.6
—
25.00
—
0
8
75
692
1.17
0.39
4.9
4.1
0.00
0.00
estimate
-0.00
16
149
20
162
1.27
0.38
1.5
1.9
—
—
—
0
0
21
172
1.26
0.37
1.5
1.8
—
—
—
0
0
12
156
0.75
0.36
4.9
5.1
5.29
5.71
kpa
0.76
12
150
6
41
1.48
0.36
1.2
1.4
—
—
—
0
0
6
41
1.48
0.36
1.0
1.2
—
—
—
0
0
43
381
1.18
0.36
5.9
4.3
0.00
0.01
estimate
0.50
15
142
6
43
1.41
0.35
1.7
1.6
—
—
—
0
0
67
617
1.16
0.35
3.3
3.0
—
—
estimate
—
0
0
76
707
1.15
0.34
4.9
4.2
0.18
0.00
estimate
0.48
17
140
6
46
1.32
0.33
1.8
1.8
—
—
—
0
0
6
46
1.32
0.33
4.7
4.8
83.90
188.12
mg/l
—
6
41
6
46
1.32
0.33
4.7
4.8
29.62
25.24
mg/l
—
6
41
37
327
1.17
0.32
2.0
2.6
—
—
—
0
0
75
701
1.14
0.30
4.9
4.1
0.00
10.68
estimate
0.50
16
152
21
244
0.84
0.26
4.9
2.9
0.14
0.83
e6/l
2.84
12
135
58
540
1.12
0.24
4.0
4.3
18.51
46.31
ng/l
2.70
36
399
16
134
1.22
0.24
4.3
3.7
—
—
—
0
0
5
37
1.36
0.24
1.2
1.7
—
—
—
0
0
5
40
1.26
0.22
1.2
1.2
—
—
—
0
0
84
801
1.11
0.22
2.9
3.1
—
—
—
0
0
8
101
0.78
0.22
1.0
1.3
—
—
—
0
0
25
221
1.16
0.22
1.8
2.3
2.37
2.35
g/l
0.08
25
199
25
221
1.16
0.22
4.2
3.1
2.31
1.74
e6/l
0.24
16
116
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
195.39
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
4.5
—
0.85
—
0
13
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
139
1369
1.23
0.18
31.0
25.4
91.06
90.72
fl
0.40
139
1358
120
1172
1.12
0.18
7.8
6.7
40.33
39.74
mmol/mol
0.33
115
1099
10
82
1.24
0.17
1.1
1.0
—
—
—
0
0
139
1370
1.22
0.17
31.0
26.0
40.46
40.33
%
0.16
139
1359
139
1370
1.22
0.17
31.2
25.6
134.15
135.11
g/l
0.35
139
1359
42
391
1.10
0.17
1.7
1.7
23.27
20.08
nmol/l
0.51
36
315
122
1194
1.12
0.16
18.9
16.5
83.05
81.36
ml/min/173m2
0.40
116
1113
8
72
1.12
0.16
1.4
1.6
—
—
—
0
0
45
425
1.08
0.13
5.1
5.5
1.45
2.09
ug/l
1.49
40
382
128
1260
1.11
0.12
6.1
5.8
2.58
2.66
mmol/l
0.44
118
1168
21
193
1.10
0.10
1.9
1.4
—
—
—
0
0
122
1238
0.92
0.10
5.1
5.1
1.50
1.45
mmol/l
0.47
109
1141
123
1247
0.92
0.09
5.3
5.2
4.49
4.56
mmol/l
0.29
113
1159
11
97
1.14
0.09
5.4
8.9
25.45
24.79
mmol/l
0.31
11
97
15
137
1.11
0.08
2.1
4.6
549.52
55.46
ug/l
—
9
119
42
407
1.04
0.05
4.0
3.2
0.47
0.36
e6/l
0.13
32
310
42
428
0.97
0.02
2.4
3.5
1817.88
1711.95
ng/l
0.05
33
363
13
137
0.94
0.01
3.2
2.9
34.38
29.96
u/l
0.27
13
107
13
137
0.94
0.01
2.6
1.8
—
—
—
0
0
25
243
1.03
0.01
2.7
3.1
0.51
0.82
ug/l
1.92
15
154
15
156
0.96
0.00
5.7
7.5
—
—
—
0
0
15
149
1.01
0.00
2.7
2.0
—
—
—
0
0
21
207
1.02
0.00
1.9
2.3
23.48
22.40
%
0.11
21
192
122
1218
1.01
0.00
5.7
5.2
5.99
5.98
mmol/l
0.02
111
1121
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.5
—
4.40
—
0
6
7
78
0.89
-0.00
1.1
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
11.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
62.30
—
0
5
0
6
0.00
-0.00
0.0
4.5
—
10.53
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
92.57
—
0
7
0
8
0.00
-0.00
0.0
6.9
—
236.63
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
20.40
—
0
5
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
44.06
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint L12_PARAPSO_PITYLICHCHRON and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_PITYLICHCHRON | 1.103 [0.81, 1.5] | 0.535 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 434 males with L12_PARAPSO_PITYLICHCHRON died.
Mortality risk
Mortality risk for people of age
years, who have L12_PARAPSO_PITYLICHCHRON.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.262% |
| 5 | No data | 1.381% |
| 10 | No data | 3.296% |
| 15 | No data | 5.941% |
| 20 | No data | 10.029% |
Relationships between endpoints
↥Index endpoint: L12_PARAPSO_PITYLICHCHRON – Pityriasis lichenoides chronica
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data